ArticleJournal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine2026
Selective Fetal Echocardiogram Referral Program for Pregnancies Affected by Pregestational Diabetes.
Article in Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesFetal echocardiography (FE) is universally recommended for pregnancies affected by pregestational diabetes. We hypothesized that in an experienced center, the use of a selective FE referral policy detects congenital heart disease (CHD) without missing clinically relevant defects.
methodsThis was a retrospective cohort study of pregnancies complicated by type 1 or 2 diabetes that underwent detailed obstetric ultrasound and delivered at a tertiary care center between July 2018 and July 2023. The primary outcome was clinically significant prenatal CHD detection, defined as CHD that may require intervention within a year of life, with a secondary outcome of all CHD detection. Detailed obstetric ultrasounds with expanded cardiac views were performed by maternal fetal medicine (MFM) sonographers, with interpretation by MFM physicians or specialized radiologists in fetal imaging. FE was ordered for other AIUM FE screening indications, suboptimal, or abnormal cardiac views. All neonates underwent standard CHD screening prior to discharge by physical exam.
resultsAmong 604 eligible pregnancies, 10 (1.7%) clinically significant CHD were diagnosed, with 56 (9.3%) total CHD in neonates. All cases of clinically significant CHD were detected prenatally, even in those with an A1C >9.0. For all minor CHD, 30 cases (53.5%) were not identified prenatally and were only identified postnatally. The postnatally detected lesions all were clinically insignificant. With selective referral, 166 (27.5%) pregnancies underwent FE, representing a significant reduction in FE performed.
conclusionIn a tertiary center with expanded cardiac imaging protocols, selective FE referral substantially reduced FE utilization while effectively identifying all clinically significant CHD in pregnancies with pregestational diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.